Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723463 · ClinicalTrials.gov registry record · Early Phase 1
Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue
A Early Phase 1 study of Brain Cancer and Neck Cancer, sponsored by University of Michigan.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00723463: Completed Early Phase 1 study of Brain Cancer and Neck Cancer, sponsored by University of Michigan.
NCT00723463 is a Early Phase 1 study of Brain Cancer and Neck Cancer that has completed, run by University of Michigan. The registered enrollment target is 200 participants, below the 503-participant average among 47 other Brain Cancer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723463, a Early Phase 1 study of Brain Cancer and Neck Cancer, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine normal measurements (ADC values) from the head and neck of healthy volunteers using 3T MRI.
Conditions Studied
Interventions
- PROCEDURE 3T MRI scan
Study Locations (1)
Michigan
- University of Michigan Health System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-06 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
What the finished NCT00723463 record still lists
NCT00723463 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 503-participant average among 47 other Brain Cancer trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which 3T MRI scan is the first listed.
NCT00723463 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT00723463 about?
NCT00723463 is a clinical study titled "Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue". The purpose of this study is to determine normal measurements (ADC values) from the head and neck of healthy volunteers using 3T MRI.
What is the current status of trial NCT00723463?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 200 participants. The study started on 2006-06. Estimated completion is 2016-07.
What conditions does trial NCT00723463 study?
This clinical trial studies the following conditions: Brain Cancer, Neck Cancer.
What interventions are being tested in trial NCT00723463?
The interventions under investigation include: 3T MRI scan (PROCEDURE).
Who is sponsoring clinical trial NCT00723463?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00723463 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00723463's enrollment target sits among peer trials
200 8th of 47 higher than 40 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET and MRI Imaging of Brain Tumors Using [18F]PARPi
COMPLETED · Early Phase 1
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia